Are you Dr. Yamashita?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 12 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3626 Torrey View CT
San Diego, CA 92130Phone+1 619-306-2125Fax+1 858-617-7705
Summary
- Dr. Mason Yamashita, MD is a psychiatrist in San Diego, California. He is currently licensed to practice medicine in California.
Education & Training
University of Hawaii, John A. Burns School of MedicineClass of 1996
Certifications & Licensure
CA State Medical License 2001 - 2024
Clinical Trials
- Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers Start of enrollment: 2012 Feb 27
- Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo Start of enrollment: 2018 Feb 27
Publications & Presentations
PubMed
- 62 citationsEmricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With PlaceboCatherine Frenette, Giuseppe Morelli, Mitchell L. Shiffman, R. Todd Frederick, Raymond A. Rubin
Clinical Gastroenterology and Hepatology. 2019-03-01 - 160 citationsSTAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J. Reilley, Patricia McCoon, Carl Cook, Paul Lyne, Razelle Kurzrock
Journal for Immunotherapy of Cancer. 2018-11-16 - 315 citationsAZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancerDavid S. Hong, Razelle Kurzrock, Youngsoo Kim, Richard Woessner, Anas Younes
Science Translational Medicine. 2015-11-18
